Surgery and HIPEC in relapse for all patients with ovarian cancer?

por Hasson, S.P., Ray-Coquard, I., Marth, C., Harter, P.
Publicado 2023

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

por Bachelot, T, Ray-Coquard, I, Menetrier-Caux, C, Rastkha, M, Duc, A, Blay, J-Y
Publicado 2003

Recurrent or primary metastatic cervical cancer: current and future treatments

por Gennigens, C., Jerusalem, G., Lapaille, L., De Cuypere, M., Streel, S., Kridelka, F., Ray-Coquard, I.
Publicado 2022

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group

por du Bois, A, Vergote, I, Wimberger, P, Ray-Coquard, I, Harter, P, Curtis, L B, Mitrica, I
Publicado 2012

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas

por Ray-Coquard, I, Ghesquière, H, Bachelot, T, Borg, C, Biron, P, Sebban, C, LeCesne, A, Chauvin, F, Blay, J-Y
Publicado 2001

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy

por Ray-Coquard, I, Borg, C, Bachelot, Th, Sebban, C, Philip, I, Clapisson, G, Le Cesne, A, Biron, P, Chauvin, F, Blay, J Y
Publicado 2003

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

por Ray-Coquard, I, Favier, L, Weber, B, Roemer-Becuwe, C, Bougnoux, P, Fabbro, M, Floquet, A, Joly, F, Plantade, A, Paraiso, D, Pujade-Lauraine, E
Publicado 2013

A controlled ‘before-after’ study: impact of a clinical guidelines programme and regional cancer network organization on medical practice

por Ray-Coquard, I, Philip, T, de Laroche, G, Froger, X, Suchaud, J-P, Voloch, A, Mathieu-Daudé, H, Fervers, B, Farsi, F, Browman, G P, Chauvin, F
Publicado 2002

A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients

por Bachelot, T, Gomez, F, Biron, P, Ray-Coquard, I, Soler-Michel, P, Philip, I, Guastalla, J P, Rebattu, P, Dumortier, A, Droz, J P, Blay, J Y
Publicado 2002

A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region

por Cassier, P A, Ducimetière, F, Lurkin, A, Ranchère-Vince, D, Scoazec, J-Y, Bringuier, P-P, Decouvelaere, A-V, Méeus, P, Cellier, D, Blay, J-Y, Ray-Coquard, I
Publicado 2010

Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the G...

por Ray-Coquard, I, Paraiso, D, Guastalla, J-P, Leduc, B, Guichard, F, Martin, C, Chauvenet, L, Haddad-Guichard, Z, Lepillé, D, Orfeuvre, H, Gautier, H, Castera, D, Pujade-Lauraine, É
Publicado 2007

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours

por Adenis, A, Ray-Coquard, I, Italiano, A, Chauzit, E, Bui-Nguyen, B, Blay, J-Y, Tresch-Bruneel, E, Fournier, C, Clisant, S, Amela, E Y, Cassier, P A, Molimard, M, Penel, N
Publicado 2013

Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay

por Verronèse, E., Delgado, A., Valladeau-Guilemond, J., Garin, G., Guillemaut, S., Tredan, O., Ray-Coquard, I., Bachelot, T., N'Kodia, A., Bardin-Dit-Courageot, C., Rigal, C., Pérol, D., Caux, C., Ménétrier-Caux, C.
Publicado 2015

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis

por Dufresne, A, Bertucci, F, Penel, N, Le Cesne, A, Bui, B, Tubiana-Hulin, M, Ray-Coquard, I, Cupissol, D, Chevreau, C, Perol, D, Goncalves, A, Jimenez, M, Bringuier, P P, Blay, J Y
Publicado 2010

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes

por Pecorelli, S., Ray-Coquard, I., Tredan, O., Colombo, N., Parma, G., Tisi, G., Katsaròs, D., Lhommé, C., Lissoni, A. A., Vermorken, J. B., du Bois, A., Poveda, A., Frigerio, L., Barbieri, P., Carminati, P., Brienza, S., Guastalla, J. P.
Publicado 2010

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group

por Cassier, P A, Lefranc, A, Y Amela, E, Chevreau, C, Bui, B N, Lecesne, A, Ray-Coquard, I, Chabaud, S, Penel, N, Berge, Y, Dômont, J, Italiano, A, Duffaud, F, Cadore, A-C, Polivka, V, Blay, J-Y
Publicado 2013

Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study

por Zhang, A Y, Judson, I, Benson, C, Wunder, J S, Ray-Coquard, I, Grimer, R J, Quek, R, Wong, E, Miah, A B, Ferguson, P C, Dufresne, A, Teh, J Y H, Stockler, M, Tattersall, M H N
Publicado 2017

Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study

por Zhang, A. Y., Judson, I., Benson, C., Wunder, J. S., Ray-Coquard, I., Grimer, R. J., Quek, R., Wong, E., Miah, A. B., Ferguson, P. C., Dufresne, A., Teh, J. Y. H., Stockler, M., Tattersall, M. H. N.
Publicado 2018

RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study()

por Mirjolet, C., Merlin, J.L., Truc, G., Noël, G., Thariat, J., Domont, J., Sargos, P., Renard-Oldrini, S., Ray-Coquard, I., Liem, X., Chevreau, C., Lagrange, J.L., Mahé, M.A., Collin, F., Bonnetain, F., Bertaut, A., Maingon, P.
Publicado 2019

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials

por Nassif, E.F., Blay, J.-Y., Massard, C., Dufresne, A., Brahmi, M., Cassier, P., Ray-Coquard, I., Pautier, P., Leary, A., Sunyach, M.-P., Bahleda, R., Levy, A., Le Pechoux, C., Honoré, C., Mir, O., Le Cesne, A.
Publicado 2022